Neue Novavax: Anstieg nach 1:20 Re-Split
Seite 50 von 354 Neuester Beitrag: 10.06.24 19:00 | ||||
Eröffnet am: | 15.05.19 08:23 | von: moneywork4. | Anzahl Beiträge: | 9.84 |
Neuester Beitrag: | 10.06.24 19:00 | von: Unicorn71 | Leser gesamt: | 2.182.182 |
Forum: | Hot-Stocks | Leser heute: | 1.274 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 47 | 48 | 49 | | 51 | 52 | 53 | ... 354 > |
Aber das ist nur meine Meinung.
……By January-February, there is a possibility that Covovax (SII-manufactured Novavax vaccine) could be ready for approval for use on children.
…SII’s Covovax (Novavax) vaccine is also expected to start production in the October quarter.
https://wap.business-standard.com/article/...h-tb7xYNVCrm_yboxSKXos_o
Novavax is expected to receive authorization from the EMA in October. And the pharmacist has already specified to this newspaper that she was prepared to start sending doses as soon as she received the 'ok' from the agency.
https://stocktwits.com/NVAX_FirstStock/message/382926791
https://www.elespanol.com/invertia/observatorios/.../613689913_0.html
Nun ja, aber wie immer gilt: erstmal muss geliefert werden, sonst wird das alles nix...
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General of India (DCGI).
"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "It represents another major milestone in Novavax' transformation into a commercial global vaccine company and reinforces the value of global collaboration and need for multiple approaches to help control the pandemic."
The grant of EUL by the WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In addition to the submission for WHO EUL, SII and Novavax last month completed the submission of modules required by regulatory agencies in India, Indonesia and the Philippines for the initiation of review of the vaccine, including preclinical, clinical, and chemistry, manufacturing and controls (CMC) data.
https://ir.novavax.com/...ncy-Use-Listing-of-Novavax-COVID-19-Vaccine
Wer will, noch sind ein paar Sitzplätze frei, es wird aber schon gedrängelt!
Novavax makes regulatory submission seeking WHO nod for COVID-19 vaccine
https://seekingalpha.com/news/...d-19-vaccine?source=copyToPasteboard